ClinicalTrials.gg
CompletedNCT04536961Updated Oct 6, 2021

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

A Phase 1 interventional study of Reference Treatment- BMS-986165-01 and Prototype BMS-986165 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-06.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • No deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations.
  • (BMI) of 18.0 to 32.0 kg/m2, inclusive, and total body weight ≥50 kg (110 lb). BMI = weight (kg)/(height [m])2 at screening.
  • Willing and able to consume 4 units of alcohol (Part B only)
  • A negative polymerase chain reaction (PCR) test for coronavirus disease 2019 (COVID-19) at screening and admission
  • Males and females must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months or 90 days of study drug administration) gastrointestinal disease that, in the opinion of the investigator or medical monitor, could impact upon the absorption of study drug
  • Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease.
  • Clinically significant history or presence of acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months or 90 days prior to screening.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Part A: Reference Treatment

    Drug: Reference Treatment- BMS-986165-01

  • Experimental
    Part A Prototype

    Drug: Prototype BMS-986165

  • Experimental
    Part C Reference Treatment

    Drug: Reference Treatment- BMS-986165-01

  • Experimental
    Part C: Prototype

    Drug: Prototype BMS-986165

  • Experimental
    Part B: Treatment 1

    Drug: Prototype BMS-986165

  • Experimental
    Part B: Treatment 2

    Drug: Prototype BMS-986165

  • Experimental
    Part B: Treatment 3

    Drug: Prototype BMS-986165

  • Experimental
    Part B: Treatment 4

    Drug: Prototype BMS-986165 · Drug: Famotidine

  • Experimental
    Part B: Treatment 5

    Drug: Prototype BMS-986165 · Other: Alcohol

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986165

    Time frame: Day 1 and Day 7

  2. Time of maximum observed plasma concentration (Tmax) of BMS-986165

    Time frame: Day 1 and Day 7

  3. Area under the plasma concentration-time curve from time zero to t (AUC (0-t)) of BMS-986165

    Part A, B, C

    Time frame: Day 1 and Day 7

Secondary outcomes

  1. Incidence of Nonserious Adverse Events (AEs)

    Time frame: Up to approximately 60 days (for Parts A & C), approximately 69 days (for Part B)

  2. Incidence of Serious Adverse Events (AEs)

    Time frame: Up to approximately 83 days (for Parts A & C), approximately 92 days (for Part B)

  3. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  4. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  5. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  6. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  7. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  8. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  9. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  10. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF

    QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  11. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS

    QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  12. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval

    The QT interval is the time from the start of the Q wave to the end of the T wave.

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

  13. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval

    PR interval is the time from the onset of the P wave to the start of the QRS complex

    Time frame: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)

07

Study locations

1 site
  • Quotient Sciences Miami
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Dec 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Sep 3, 2020
StartActual
Sep 10, 2020
Primary completionActual
Dec 25, 2020
CompletionActual
Dec 25, 2020
Last update
Oct 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536961
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Sep 10, 2020
Primary completion
Dec 25, 2020
Completion
Dec 25, 2020
Last update
Oct 6, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion